Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes

Table 2 Mode of blood purification therapy according to disease

	Acute kidney injury	Sepsis	Congestive heart failure	Multiple organ failure	Acute liver failure	Acute electrolyte disorders	Autoimmune diseases	Severe acute pancreatitis	Acute lung injury	Thrombotic microangiopathy	Acute drug intoxication
Cumulative number of patients	1182	680	336	190	90	137	52	44	106	32	18
CRRT	880 (74.4)	418 (61.5)	276 (82.1)	113 (59.5)	36 (40.0)	86 (62.8)	8 (15.4)	40 (90.9)	58 (54.7)	6 (18.8)	11 (61.1)
CHDF	579 (50.0)	328 (48.2)	224 (66.7)	76 (40.0)	28 (31.1)	59 (43.1)	3 (5.8)	35 (79.5)	36 (34.0)	4 (12.5)	4 (22.2)
CHD	209 (17.7)	53 (7.8)	41 (12.2)	27 (14.2)	7 (7.8)	18 (13.1)	1 (1.9)	1 (2.3)	16 (15.1)	2 (6.3)	7 (38.9)
CHF	92 (7.8)	37 (5.4)	11 (3.3)	10 (5.3)	1 (1.1)	9 (6.6)	4 (7.7)	4 (9.1)	6 (5.7)	0 (0)	0 (0)
SLED	21 (1.8)	1 (0.1)	2 (0.6)	1 (0.5)	1 (1.1)	0 (0)	0 (0)	0 (0)	2 (1.9)	0 (0)	0 (0)
IRRT	281 (23.8)	73	58 (17.2)	32 (16.8)	11 (12.2)	51 (37.2)	5 (9.6)	4 (9.1)	22 (20.8)	7 (21.9)	3 (16.7)
Direct hemoperfusion with PMX	0 (0)	188 (27.5)	0 (0)	8 (4.2)	0 (0)	0 (0)	0 (0)	0 (0)	13 (12.3)	0 (0)	0 (0)
Direct hemoperfusion with activated carbon	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (22.2)
Simple plasma exchange	0 (0)	0 (0)	0 (0)	35 (18.4)	36 (40.0)	0 (0)	25 (48.1)	0 (0)	11 (10.4)	19 (59.4)	0 (0)
Double filtration plasmapheresis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (11.5)	0 (0)	0 (0)	0 (0)	0 (0)
Plasma adsorption	0 (0)	0 (0)	0 (0)	1 (0.5)	3 (3.3)	0 (0)	8 (15.4)	0 (0)	0 (0)	0 (0)	0 (0)
Others	0 (0)	0 (0)	0 (0)	0 (0)	3 (3.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Data are expressed as n or n (%). CHF, continuous hemofiltration; CHD, continuous hemodialysis, CHDF, continuous hemodiafiltration; CRRT, continuous renal replacement therapy; PMX, polymyxin B-immobilized fiber column; IRRT, intermittent renal replacement therapy; SLED, sustained low-efficiency hemodialysis. Continuous renal replacement therapy, typically performed for 24 h, is divided into continuous hemodiafiltration, continuous hemodialysis, and continuous hemofiltration. Intermittent renal replacement therapy, typically performed in 4-h session 3 times weekly, includes intermittent hemodialysis or intermittent hemodiafiltration. Direct hemoperfusion with PMX is indicated for endotoxemia or sepsis due to gram-negative bacillus as well as severe sepsis. Direct hemoperfusion with activated carbon is mainly indicated for acute drug intoxication. Double filtration plasmapheresis and plasma adsorption are indicated in autoimmune diseases for removal or adsorption of autoantibodies. Simple plasma exchange is indicated in liver failure, autoimmune diseases, HUS, TTP, Guillain–Barré syndrome, and toxic epidermal necrolysis, among other conditions

ISSN: 2059-1381